The AIF1 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human osteosarcoma cell line 143B, designed for functional studies of the allograft inflammatory factor 1 (AIF1) gene. This product provides a heterogeneous pool of cells carrying targeted disruptions in the AIF1 locus, enabling loss-of-function analyses without clonal selection biases. The polyclonal format ensures representation of diverse editing events, making it suitable for examining AIF1-dependent phenotypes in a cancer cell background.
The 143B cell line is a human osteosarcoma model, originally derived from the HOS (TK-) osteosarcoma line, widely used in bone cancer research for studying tumor growth, metastasis, and therapeutic responses. Its tumorigenic properties and ability to form bone tumors in xenograft models make it a relevant platform for investigating gene functions in the context of osteosarcoma biology.
AIF1 encodes a calcium-binding protein that modulates actin cytoskeleton reorganization and promotes inflammatory responses. It is activated by upstream stimuli such as TNF-??, IL-1??, LPS, and IFN-??, acting through NF-??B and STAT1 signaling. AIF1 interacts with F-actin and Ca2? ions, and activates Rac1 to influence actin polymerization. Downstream, it enhances production of pro-inflammatory cytokines including TNF-?? and IL-6, and regulates cell migration and phagocytosis. In the MAPK and NF-??B pathways, AIF1 functions as an adaptor integrating immune signals with cytoskeletal dynamics.
In the 143B osteosarcoma background, AIF1 knockout may impair inflammatory signaling, reduce cytokine secretion, and attenuate migratory and invasive capacities, providing a model to dissect AIF1-dependent tumor inflammation. As osteosarcoma progression is influenced by the inflammatory tumor microenvironment, this cell pool enables investigation of how AIF1-mediated cytoskeletal and signaling changes contribute to cancer cell aggression and interaction with immune components.
Researchers can employ these polyclonal knockout cells in a variety of assays including western blotting, RT-qPCR, immunofluorescence, migration and invasion assays, ELISA-based cytokine quantification, phagocytosis assays, NF-??B reporter assays, and flow cytometry. Applications span inflammation research, cancer biology focusing on the tumor microenvironment, macrophage-like functional studies in a cancer context, bone cancer mechanistic studies, drug screening for anti-inflammatory agents, and immune modulation investigations. For additional details or custom requests, please contact Ascent Research.
